Zenas BioPharma

ZBIO · Nasdaq · United States

Share price · ZBIO

$26.42-5.49 (-17.20%) 3M

close as of 2026-11-18 · 24h delayed · vol 480K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ZBIO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+9.0%
  2. 8 Oct 2026-6.9%
  3. 24 Sep 2026-7.2%

    Nothing announced by ZBIO that day or the session before.

  4. 1 Jul 2026+10.3%

    Nothing announced by ZBIO that day or the session before.

  5. 25 Jun 2026+13.2%

    Nothing announced by ZBIO that day or the session before.

  6. 12 Jun 2026+11.5%

    Nothing announced by ZBIO that day or the session before.

  7. 4 May 2026+11.4%

    Nothing announced by ZBIO that day or the session before.

  8. 12 Jan 2026+23.0%

    Nothing announced by ZBIO that day or the session before.

  9. 5 Jan 2026-51.9%
  10. 22 Dec 2025+17.1%

Share of unusual movement by asset

For each asset, the share of ZBIO's own-move activity since 17 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Obexelimab
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—30%
Other company news (earnings, financing, releases naming no asset)—1%
Sessions with no dated event—69%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
CD19 / FcγRIIbMonoclonal antibody
Systemic Lupus ErythematosusIgG4-Related Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

27 May 2027FDA action dateobexelimabObexelimab BLA PDUFA target action date
US, FDA · Zenas BioPharma · Source ↗

Recent

August 2026Filing acceptedobexelimabFDA accepts obexelimab BLA for IgG4-related disease
US, FDA · Zenas BioPharma · Source ↗
5 January 2026Topline resultObexelimabINDIGO Phase 3 (NCT05662241) met its primary endpoint: 56% lower risk of IgG4-RD flare vs placebo (HR 0.44)

Financial reports

Quarterly & interim (10)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$10M$58M$178M+ $408M short-term inv.$109M-$58M operating cash flowreport ↗
View 9 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.0M$63M$197M+ $447M short-term inv.$111M-$57M operating cash flowreport ↗
2026-Q1—$60M$500M+ $217M short-term inv.$81M-$75M operating cash flowreport ↗
2025-Q3$0$34M$116M+ $175M short-term inv.$52M-$41M operating cash flowreport ↗
2025-Q2$0$43M$44M+ $229M short-term inv.$52M-$42M operating cash flowreport ↗
2025-Q1$10M$35M$197M+ $116M short-term inv.$34M-$37M operating cash flowreport ↗
2024-Q3$0$34M$360M+ $27M short-term inv.$39M-$31M operating cash flowreport ↗
2024-Q2$0$34M$184M$38M-$31M operating cash flowreport ↗
2024-Q1—$23M$37M$28M-$19M operating cash flowreport ↗
2023-Q3$50M$9.3M$72M—report ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$10M$168M$111M+ $233M short-term inv.$94M-$172M operating cash flowreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$5.0M$139M$320M+ $31M short-term inv.$39M-$120M operating cash flowreport ↗
2023-FY$50M$60M$57M$9.3M-$31M operating cash flowreport ↗
2022-FY——$67M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 17 purchases ($11.4M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-01Oliger Christy J. · directorAward / grant (derivative)37,000——Form 4
2026-06-15ENRIGHT PATRICK G · directorAward / grant (derivative)18,500——Form 4
2026-06-15Boylan James P · directorAward / grant (derivative)18,500——Form 4
2026-06-15Allen Patricia L · directorAward / grant (derivative)18,500——Form 4
2026-06-15von Moltke Lisa · See RemarksAward / grant (derivative)150,000——Form 4
2026-06-15ORLOFF JOHN J · directorAward / grant (derivative)18,500——Form 4
2026-06-15MOULDER LEON O JR · director, See RemarksAward / grant (derivative)500,000——Form 4
2026-06-15Lu Hongbo · directorAward / grant (derivative)18,500——Form 4